Nusinersen corrects L-arginine deficiency in the cerebrospinal fluid of patients with severe spinal muscular atrophy
Spinal Muscular Atrophy (SMA) is a progressive neuromuscular disorder caused by homozygous loss of the survival motor neuron 1 (SMN1) gene, leading to reduced SMN protein expression. Increasing evidence implicates neurotransmission deficits in the pathophysiology of SMA. In particular, alterations i...
Saved in:
| Main Authors: | Amber Hassan, Raffaella di Vito, Anna Caretto, Tommaso Nuzzo, Adele D'Amico, Chiara Panicucci, Claudio Bruno, Enrico Bertini, Alessandro Vercelli, Marina Boido, Francesco Errico, Livio Pellizzoni, Alessandro Usiello |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-10-01
|
| Series: | Neurobiology of Disease |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0969996125002621 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The efficacy and safety of nusinersen within the expanded access program in Russia
by: S. B. Artemieva, et al.
Published: (2020-12-01) -
Common complications in spinal muscular atrophy (SMA) type 1 after nusinersen treatment
by: Yiğithan Güzin, et al.
Published: (2024-11-01) -
Dysregulated balance of D- and L-amino acids modulating glutamatergic neurotransmission in severe spinal muscular atrophy
by: Amber Hassan, et al.
Published: (2025-04-01) -
Experience of Nusinersen in children with proximal spinal muscular atrophy 5q in Moscow region
by: M. V. Panteleeva
Published: (2022-12-01) -
Long‐Term Effects of Nusinersen Dosing Frequency on Adult Patients With Spinal Muscular Atrophy: Efficacy of a 6‐Month Dosing Interval
by: Keita Takahashi, et al.
Published: (2025-05-01)